PEDIATRICS

AMERICAN ACADEMY OF

PEDIATRICS

EVANSTON ILLINOIS

60204

SUPPLEMENT

HEXACHLOROPHENE—Its Usage in the Nursery

Proceedings of a Conference held in Stowe, Vermont, under the auspices of the University of Vermont School of Medicine, June 1972

PEDIATRICS is owned, controlled and published monthly by the American Academy of Pediatrics, Inc. Subscription price per year: U.S., Canada, Mexico, Cuba, Central and South America, \$17.00; other countries, \$24.00. For special price for medical students, hospital residents, and fellows in full time training, please consult publisher. Current single issues, \$2.00.

Second-Class postage paid at EVANSTON, ILLINOIS, and at additional mailing office, under the Act of March 3, 1879. Acceptance at a special rate of postage, as provided in Section 3440D, authorized November 18, 1952.

Copyright, © 1973, by the American Academy of Pediatrics, Inc. Printed in U.S.A.

No part may be duplicated or reproduced without permission of publishers.

Copies of this supplement may be obtained for \$2.00 each from: The American Academy of Pediatrics, 1801 Hinman Avenue, Evanston, Illinois 60204.

INTRODUCTION

This conference was held in Stowe, Vermont under the auspices of the Department of Pediatrics, University of Vermont School of Medicine with funds donated by Winthrop Laboratories.

The purpose of the conference was to assemble as much of the recent and past evidence bearing on hexachlorophene and its usage in the nursery as was available at the time (June 1972) and to publish these studies as rapidly as possible so that physicians would be well informed on the subject.

The reader will find both sides of the argu-

ment about hexachlorophene presented and commented upon. I believe that, if he reads this tome, he will have a great deal more sympathy and understanding for the complexity of the problems involved. When one listens to experts in conflict, decisions are never easy. However, it is my hope that this publication will serve the practicing pediatrician by furnishing him with a clear view of both sides of the issue.

JEROLD F. LUCEY, M.D., F.A.A.P. Professor of Pediatrics University of Vermont

PARTICIPANTS

Mr. August Curley, Environmental Protection Agency, Chamblee, Georgia.

Laurence Finberg, M.D., Professor and Chairman, Department of Pediatrics, Albert Einstein College of Medicine, New York City.

Floyd H. Gilles, M.D., Assistant Professor of Neuropathology, Harvard Medical School, Boston.

Theodore F. Hatch, Sc.D., Professor Emeritus, School of Public Health, University of Pittsburgh, Pennsylvania.

W. Alan Hodson, M.D., Associate Professor of Pediatrics, University of Washington, Seattle.

Florabel G. Mullick, M.D., Armed Forces Institute of Pathology, Washington, District of Columbia.

Thomas K. Oliver, M.D., Professor and Chairman, Department of Pediatrics, University of Pittsburgh.

John C. Ribble, M.D., Associate Professor of Pediatrics, Cornell University, New York City.

Henry R. Shinefield, M.D., Professor of Pediatrics, University of California, San Francisco.

James M. Sutherland, M.D., Professor of Pediatrics, University of Cincinnati.

MODERATORS

Sydney S. Gellis, M.D., Professor and Chairman, Department of Pediatrics, Tufts University, Boston, Massachusetts.

L. Stanley James, M.D., Professor of Pediatrics, Columbia University, New York City.

Jerold F. Lucey, M.D., Professor of Pediatrics, University of Vermont, Burlington.

R. James McKay, Jr., M.D., Professor and Chairman, Department of Pediatrics, University of Vermont, Burlington.

SPEAKERS

Alex G. M. Campbell, M.D., Associate Professor of Pediatrics, Yale University, New Haven, Connecticut.

Horace Gezon, M.D., Professor of Pediatrics, Boston University, Boston.

Louis Gluck, M.D., Professor of Pediatrics, University of California, San Diego.

Renate D. Kimbrough, M.D., Environmental Protection Agency, Chamblee, Georgia.

Jerome O. Klein, M.D., Associate Professor of Pediatrics, Boston University, Boston.

Irwin J. Light, M.D., Assistant Professor of Pediatrics and Obstetrics and Gynecology, University of Cincinnati, Ohio

V. D. Plueckhahn, M.D., Director Medical Services, Geelong Hospital, Victoria, Australia.

GUESTS

Joyce Abel, M.D., Medical Director, Winthrop Laboratories, Toronto, Canada.

William P. Blackmore, M.D., Director of Clinical Research, Winthrop Laboratories, New York City.

Harvey Blank, M.D., Professor of Dermatology, University of Miami, Florida.

Richard L. Davis, M.D., Chief of Neuropathology, University of Southern California, Los Angeles.

Julian Dorsky, M.D., Vice-President of Research, Givaudan Corporation, New York City.

Ben R. Forsyth, M.D., Chairman, Infectious Disease Unit, University of Vermont, Burlington.

Edwin Gresham, M.D., Assistant Professor of Pediatrics, Indiana University Medical Center, Indianapolis.

Dieter W. Gump, M.D., Associate Professor of Medi-

cine, Infectious Disease Unit, University of Vermont, Burlington.

Mr. A. J. Hamel, Infections Surveillance Officer, Medical Center Hospital of Vermont, Burlington.

Harold W. Hermann, M.D., Director of Clinical Investigation, Mead Johnson Research Center, Evansville, Indiana.

Irwin S. Kaye, M.D., Assistant Professor of Pathology, University of Vermont, Burlington.

M. Manowitz, Ph.D., Associate Director of Research, Givaudan Corporation, New York City.

G. Warren McCarl, M.D., Associate Medical Director,

Winthrop Laboratories, New York City.

James Mitchell, M.D., Epidemiologist, Vermont State Department of Health, Burlington.

C. Alan Phillips, M.D., Associate Professor of Medicine, Infectious Disease Unit, University of Vermont, Burlington.

Monica Shaberg, M.D., Research Fellow in Neonatology, Boston University, Boston.

J. B. Spooner, M.D., Director, Sterling-Winthrop Group Ltd., United Kingdom.

Monroe E. Trout, M.D., Medical Director, Winthrop Laboratories, New York City.

our discussion. I would like to thank Dr. McKay and Dr. Lucey for organizing the conference through many trials and tribulations of acceptances and refusals. I would also like to thank Dr. Trout of Winthrop Laboratories for providing the financial support for the conference. And now Dr. Lucey for the final comments.

Dr. Lucey: A conference of this type is set up to explore all that is known on a subject and the end result is usually a better understanding of what is not known. There is still a great deal of ignorance on the subject of HCP. Much needs to be learned. There is a great need for more carefully planned studies, especially in the area of neurotoxicity. It is not possible to legislate one's way out of ignorance. A ban on hexachlorophene would be as bad as legislation forcing us to use it. I am glad we have been able to end on a rational compromise note. Thank you all for coming.

The following two articles by Dr. Richard E. Dixon, et al., and Dr. Richard A. Kaslow, et al., and the statement from the Food and Drug Administration were not presented at the conference. They have been included in this supplement because of their important relevance to the subject. Comments written by Dr. James M. Sutherland and Dr. Monroe E. Trout have also been included for the readers.